Cyclo Revenue Per Share vs Ebit Per Revenue Analysis

CYTHW Stock

USD 0.09 0.03 24.17%

Cyclo Therapeutics financial indicator trend analysis is way more than just evaluating Cyclo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cyclo Therapeutics is a good investment. Please check the relationship between Cyclo Therapeutics Revenue Per Share and its Ebit Per Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

Revenue Per Share vs Ebit Per Revenue

Revenue Per Share vs Ebit Per Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cyclo Therapeutics Revenue Per Share account and Ebit Per Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Cyclo Therapeutics' Revenue Per Share and Ebit Per Revenue is 0.61. Overlapping area represents the amount of variation of Revenue Per Share that can explain the historical movement of Ebit Per Revenue in the same time period over historical financial statements of Cyclo Therapeutics, assuming nothing else is changed. The correlation between historical values of Cyclo Therapeutics' Revenue Per Share and Ebit Per Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Revenue Per Share of Cyclo Therapeutics are associated (or correlated) with its Ebit Per Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit Per Revenue has no effect on the direction of Revenue Per Share i.e., Cyclo Therapeutics' Revenue Per Share and Ebit Per Revenue go up and down completely randomly.

Correlation Coefficient

0.61

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Ebit Per Revenue

Most indicators from Cyclo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cyclo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.At this time, Cyclo Therapeutics' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 11.3 M in 2025, whereas Enterprise Value Over EBITDA is likely to drop (1.07) in 2025.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	16.8M	17.6M	21.0M	22.1M
Cost Of Revenue	138.9K	3.5M	98.5K	93.5K

Total Operating Expenses Cost Of Revenue

Cyclo Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Common Stock Total Equity	Property Plant And Equipment Gross	Other Current Liab
Total Assets		0.26	0.79	0.87	-0.13	-0.93	-0.76	0.85	0.98	-0.27	-0.38	0.98	0.62	0.72	-0.26	-0.17	0.61	0.83	0.79	0.99	0.34	-0.28	-0.41	-0.55	-0.14	0.49
Short Long Term Debt Total	0.26		0.49	-0.04	0.65	0.08	-0.43	0.27	0.08	0.54	0.25	0.08	-0.29	0.62	0.37	-0.14	0.52	0.46	0.54	0.16	0.7	-0.22	-0.38	-0.52	0.64	-0.51
Total Current Liabilities	0.79	0.49		0.39	-0.12	-0.6	-0.93	0.96	0.72	-0.3	-0.47	0.72	0.21	0.97	-0.13	-0.19	0.79	0.97	1.0	0.79	0.61	-0.22	-0.2	-0.43	-0.15	0.4
Total Stockholder Equity	0.87	-0.04	0.39		-0.14	-0.93	-0.41	0.51	0.9	-0.2	-0.23	0.9	0.78	0.31	-0.29	-0.06	0.29	0.48	0.38	0.86	0.04	-0.24	-0.44	-0.46	-0.13	0.45
Property Plant And Equipment Net	-0.13	0.65	-0.12	-0.14		0.37	0.29	-0.33	-0.27	0.98	0.69	-0.27	-0.35	-0.04	0.0	0.11	-0.26	-0.23	-0.08	-0.27	0.12	-0.13	-0.1	-0.12	0.99	-0.79
Net Debt	-0.93	0.08	-0.6	-0.93	0.37		0.64	-0.74	-0.98	0.47	0.48	-0.98	-0.74	-0.49	0.29	0.16	-0.47	-0.67	-0.58	-0.95	-0.16	0.21	0.38	0.44	0.37	-0.64
Retained Earnings	-0.76	-0.43	-0.93	-0.41	0.29	0.64		-0.92	-0.71	0.44	0.57	-0.71	-0.3	-0.93	-0.12	0.22	-0.92	-0.98	-0.92	-0.79	-0.73	0.25	0.31	0.49	0.29	-0.43
Accounts Payable	0.85	0.27	0.96	0.51	-0.33	-0.74	-0.92		0.82	-0.48	-0.59	0.82	0.39	0.87	-0.18	-0.24	0.76	0.95	0.94	0.87	0.47	-0.24	-0.15	-0.36	-0.35	0.6
Cash	0.98	0.08	0.72	0.9	-0.27	-0.98	-0.71	0.82		-0.39	-0.45	1.0	0.68	0.62	-0.31	-0.17	0.54	0.77	0.71	0.99	0.23	-0.23	-0.39	-0.5	-0.28	0.6
Non Current Assets Total	-0.27	0.54	-0.3	-0.2	0.98	0.47	0.44	-0.48	-0.39		0.8	-0.39	-0.36	-0.22	0.03	0.12	-0.39	-0.4	-0.25	-0.4	-0.01	-0.14	-0.03	-0.01	0.98	-0.81
Non Currrent Assets Other	-0.38	0.25	-0.47	-0.23	0.69	0.48	0.57	-0.59	-0.45	0.8		-0.45	-0.25	-0.41	0.01	0.02	-0.51	-0.54	-0.42	-0.48	-0.28	-0.18	0.05	0.12	0.69	-0.58
Cash And Short Term Investments	0.98	0.08	0.72	0.9	-0.27	-0.98	-0.71	0.82	1.0	-0.39	-0.45		0.68	0.62	-0.31	-0.17	0.54	0.77	0.71	0.99	0.23	-0.23	-0.39	-0.5	-0.28	0.6
Net Receivables	0.62	-0.29	0.21	0.78	-0.35	-0.74	-0.3	0.39	0.68	-0.36	-0.25	0.68		0.16	-0.25	-0.07	0.22	0.32	0.2	0.65	-0.15	-0.26	-0.07	-0.07	-0.32	0.56
Common Stock Shares Outstanding	0.72	0.62	0.97	0.31	-0.04	-0.49	-0.93	0.87	0.62	-0.22	-0.41	0.62	0.16		0.0	-0.19	0.84	0.96	0.97	0.71	0.7	-0.18	-0.29	-0.52	-0.07	0.26
Non Current Liabilities Total	-0.26	0.37	-0.13	-0.29	0.0	0.29	-0.12	-0.18	-0.31	0.03	0.01	-0.31	-0.25	0.0		-0.18	0.46	0.02	-0.12	-0.25	0.48	-0.05	-0.33	-0.25	0.04	-0.36
Inventory	-0.17	-0.14	-0.19	-0.06	0.11	0.16	0.22	-0.24	-0.17	0.12	0.02	-0.17	-0.07	-0.19	-0.18		-0.26	-0.21	-0.24	-0.18	0.03	-0.43	0.49	0.49	0.12	0.06
Other Current Assets	0.61	0.52	0.79	0.29	-0.26	-0.47	-0.92	0.76	0.54	-0.39	-0.51	0.54	0.22	0.84	0.46	-0.26		0.89	0.78	0.63	0.79	-0.19	-0.41	-0.54	-0.25	0.26
Other Stockholder Equity	0.83	0.46	0.97	0.48	-0.23	-0.67	-0.98	0.95	0.77	-0.4	-0.54	0.77	0.32	0.96	0.02	-0.21	0.89		0.96	0.84	0.66	-0.24	-0.32	-0.52	-0.25	0.44
Total Liab	0.79	0.54	1.0	0.38	-0.08	-0.58	-0.92	0.94	0.71	-0.25	-0.42	0.71	0.2	0.97	-0.12	-0.24	0.78	0.96		0.78	0.6	-0.23	-0.22	-0.45	-0.11	0.36
Total Current Assets	0.99	0.16	0.79	0.86	-0.27	-0.95	-0.79	0.87	0.99	-0.4	-0.48	0.99	0.65	0.71	-0.25	-0.18	0.63	0.84	0.78		0.33	-0.24	-0.39	-0.52	-0.28	0.58
Short Term Debt	0.34	0.7	0.61	0.04	0.12	-0.16	-0.73	0.47	0.23	-0.01	-0.28	0.23	-0.15	0.7	0.48	0.03	0.79	0.66	0.6	0.33		-0.19	-0.33	-0.46	0.15	-0.18
Intangible Assets	-0.28	-0.22	-0.22	-0.24	-0.13	0.21	0.25	-0.24	-0.23	-0.14	-0.18	-0.23	-0.26	-0.18	-0.05	-0.43	-0.19	-0.24	-0.23	-0.24	-0.19		-0.32	-0.26	-0.16	-0.3
Common Stock	-0.41	-0.38	-0.2	-0.44	-0.1	0.38	0.31	-0.15	-0.39	-0.03	0.05	-0.39	-0.07	-0.29	-0.33	0.49	-0.41	-0.32	-0.22	-0.39	-0.33	-0.32		0.96	-0.11	0.23
Common Stock Total Equity	-0.55	-0.52	-0.43	-0.46	-0.12	0.44	0.49	-0.36	-0.5	-0.01	0.12	-0.5	-0.07	-0.52	-0.25	0.49	-0.54	-0.52	-0.45	-0.52	-0.46	-0.26	0.96		-0.11	0.16
Property Plant And Equipment Gross	-0.14	0.64	-0.15	-0.13	0.99	0.37	0.29	-0.35	-0.28	0.98	0.69	-0.28	-0.32	-0.07	0.04	0.12	-0.25	-0.25	-0.11	-0.28	0.15	-0.16	-0.11	-0.11		-0.8
Other Current Liab	0.49	-0.51	0.4	0.45	-0.79	-0.64	-0.43	0.6	0.6	-0.81	-0.58	0.6	0.56	0.26	-0.36	0.06	0.26	0.44	0.36	0.58	-0.18	-0.3	0.23	0.16	-0.8

Click cells to compare fundamentals

Cyclo Therapeutics Account Relationship Matchups

Cyclo Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	14.2M	19.5M	4.2M	13.2M	15.2M	16.0M
Total Current Liabilities	3.7M	3.8M	3.5M	8.5M	9.7M	10.2M
Total Stockholder Equity	10.5M	15.7M	734.5K	4.8M	5.5M	5.7M
Property Plant And Equipment Net	87.9K	77.2K	56.7K	929.3K	1.1M	708.5K
Net Debt	(12.7M)	(16.4M)	(1.5M)	(8.2M)	(7.4M)	(7.0M)
Retained Earnings	(34.1M)	(48.3M)	(63.8M)	(83.9M)	(75.5M)	(71.7M)
Accounts Payable	3.5M	3.7M	2.2M	4.9M	5.6M	5.9M
Cash	12.8M	16.6M	1.5M	9.2M	10.6M	11.2M
Non Current Assets Total	137.7K	84.5K	56.7K	929.3K	836.4K	696.5K
Non Currrent Assets Other	49.8K	7.3K	(56.7K)	38.3K	34.5K	32.8K
Cash And Short Term Investments	12.8M	16.6M	1.5M	9.2M	10.6M	11.2M
Net Receivables	111.8K	539.1K	55.0K	122.4K	140.7K	106.4K
Common Stock Shares Outstanding	1.6M	6.4M	8.4M	16.3M	18.8M	19.7M
Liabilities And Stockholders Equity	14.2M	19.5M	4.2M	13.2M	15.2M	16.0M
Non Current Liabilities Total	62.9K	18.0K	3.5M	22.5K	25.9K	24.6K
Inventory	237.9K	227.4K	254.5K	254.4K	292.5K	251.9K
Other Current Assets	854.4K	2.1M	4.6M	2.7M	3.1M	3.3M
Other Stockholder Equity	44.5M	64.0M	64.5M	88.6M	101.9M	107.0M
Total Liab	3.7M	3.8M	3.5M	8.5M	9.8M	10.3M
Total Current Assets	14.1M	19.4M	4.2M	12.3M	14.2M	14.9M
Common Stock	477.0	841.0	849.0	2.9K	3.3K	3.6K
Common Stock Total Equity	9.1K	12.2K	477.0	849.0	976.35	927.53
Property Plant And Equipment Gross	87.9K	159.3K	158.2K	1.1M	945.1K	533.5K
Other Current Liab	3.5M	3.7M	1.2M	1.6M	2.6M	2.7M
Capital Surpluse	18.7M	26.0M	44.5M	64.5M	74.2M	77.9M
Property Plant Equipment	18.6K	64.6K	87.9K	55.2K	63.5K	51.7K
Net Invested Capital	10.6M	15.8M	734.5K	4.8M	5.5M	5.5M
Net Working Capital	10.4M	15.6M	677.9K	3.9M	4.4M	5.2M
Capital Stock	477.0	841.0	849.0	2.9K	2.6K	3.5K
Capital Lease Obligations	35.9K	19.2K	0.0	1.0M	1.2M	1.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Cyclo Stock Analysis

When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cyclo Revenue Per Share vs Ebit Per Revenue Analysis

Revenue Per Share vs Ebit Per Revenue

Revenue Per Share vs Ebit Per Revenue Correlation Analysis

Correlation Coefficient

Revenue Per Share

Ebit Per Revenue

Cyclo Therapeutics fundamental ratios Correlations

Cyclo Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cyclo Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Cyclo Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments

Other Stockholder Equity	- 0.98	Retained Earnings
Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Total Current Assets	- 0.95	Net Debt
Common Stock Shares Outstanding	- 0.93	Retained Earnings
Net Debt	- 0.93	Total Stockholder Equity